S&P Animal Health Partnering Oct 2023
Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
Search
FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) for Asthma | BI US
FDA approval of SPIRIVA RESPIMAT for maintenance treatment of asthma in patients 12 and older marks a new class of treatment with once-daily prescriptions.
US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease
US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned.
Protein Degraders: Changing the Game in Cancer Drug Discovery
Protein Degraders: Changing the Game in Cancer Drug Discovery
FDA Reaffirms Safety of Pradaxa® (dabigatran etexilate) | Boehringer Ingelheim US
An FDA study found that PRADAXA was associated with reduced risks of ischemic stroke, intracranial hemorrhage & death. View ISI, PI & Med Guide.
FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection)
FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection)
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
BI Presents Combination Data of Tiotropium + Olodaterol | Boehringer Ingelheim US
BI presented the first data from the pivotal Phase III TONADO™ 1&2 studies for the FDC of tiotropium plus olodaterol delivered via the Respimat® inhaler.
Words of Health and Hope
Click here to hear from our patients, who have expressed to us in beautifully written thank you notes for our BI Cares Patient Assistance Program.
The Core of our Leitbild
Click here to find out more about Boehringer Ingelheim's core values and mission statement, highlighting our key business focuses.
Clinical Development and Operations
Click here to find out more on how Boehringer Ingelheim is proud to offer a new 2-year Fellowship program within Clinical Operations.
Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
Rising Star Leads with Determination | Boehringer Ingelheim US
Click to find out more on our partnership with the HBA, where we honor a BI colleague as a “Rising Star” to support the advancement of women in health care.
Heart Failure
Heart Failure
MERIAL: RECOMBITEK® Oral Bordetella Vaccine | Boehringer Ingelheim US
MERIAL, now part of Boehringer Ingelheim, grows canine vaccine portfolio with the introduction of the RECOMBITEK® Oral Bordetella vaccine.
Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin
Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin
Protecting a Way of Life in Haiti | Boehringer Ingelheim US
Click here to find out how Boehringer Ingelheim is helping to protect a way of life in Haiti by producing a custom swine vaccine to support the island.
Employees compassionately help local communities with country-wide food drive
Coming together to bring food to people in need
Vampire Bats & Rabies: A Potential New Threat | Boehringer Ingelheim US
Read more on the emerging threat of rabid vampire bats in the Southern US. Helping prevent this disease preserves the lives of livestock worldwide.
Advancing a Vision for Pioneering Treatments in Diabetic Macula Ischemia
Advancing a Vision for Pioneering Treatments in Diabetic Macula Ischemia
Netherlands
Netherlands
Skin and Inflammatory Diseases
skin diseases
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
Medicines reach record number of people, net sales rise
Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients
Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients